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doi:10.1016/j.jtcvs.2004.03.040408 The Journal of Thoracic and CardioBackground: The favorable effects of lung volume reduction surgery for selected
patients with smoker’s emphysema has been demonstrated. However, outcome data
for patients with 1-antitrypsin deficiency emphysema are scarce.
Methods: We prospectively studied pulmonary function, dyspnea, and 6-minute
walking distance in 21 patients with severe 1-antitrypsin deficiency emphysema
(PiZZ 18, PiZO 1, PiSZ 2, 10 female patients, median age 56 years, range 38-74
years) for as long as 5 years after thoracoscopic lung volume reduction surgery.
Results: Lung volume reduction surgery improved the mean dyspnea score, from 3.7
 0.1 preoperatively to 1.4  0.2 at 3 months; the score remained improved for as
long as 3.5 years. Mean vital capacity (% predicted) improved from 79%  4.4%
to 98%  4.8% at 3 months, and the ratio of residual volume to total lung capacity
decreased from 0.67 to 0.51. These improvements lasted for as long as 2 years. The
mean airflow obstruction (forced expiratory volume in 1 second % predicted)
improved from 27%  1.9% to 38%  3.3% at 3 months and remained statistically
improved for 1 year. Four patients showed long-term improvement in lung function
for as long as 3.5 years. These patients had markedly heterogeneous emphysema and
showed no radiologic signs of airway inflammation.
Conclusions: Lung volume reduction surgery in patients with advanced emphysema
from 1-antitrypsin deficiency results in a significant improvement in dyspnea and
lung function for as long as 3.5 years in some cases. It appears that magnitude and
duration of these effects are inferior and shorter than those in patients with pure
smoker’s emphysema. Patients with heterogeneous disease and no or minor inflam-
matory airway disease may benefit most.
Lung volume reduction surgery (LVRS) is a successful palliativetherapy for carefully selected patients with end-stage emphysema.Several prospective single-center case studies1-5 and a few random-ized, controlled trials6-11 have shown that LVRS improves lungfunction, exercise capacity, and quality of life.12 Only twogroups13,14 have reported on the effect of LVRS in 1-antitrypsin
deficiency emphysema (A1-ATD). In the 12 patients described by Cassina and
coworkers,13 pulmonary function had improved comparably to that seen with
smoker’s emphysema at 3 months but returned to baseline after 6 to 12 months. In
a small group of only 6 patients, Gelb and associates14 observed variable functional
improvements between 2 and 3 years after LVRS. Prospective long-term studies in
a larger group of patients have not been published to date. We therefore prospec-
tively studied the course of dyspnea, pulmonary function, and exercise tolerance in
21 patients with A1-ATD emphysema for as long as 5 years after surgery.
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Patients
From May 1994 to March 2003, a total of 21 patients with a
median age of 56 years (range 38-74 years), with A1-ATD were
enrolled in an ongoing prospective trial on the outcome of LVRS15
that was approved by the ethical committee of our hospital. All
patients had severe A1-ATD: 18 patients were homozygous (PiZZ
phenotype) and 3 were heterozygous (1 with PiZO and two pa-
tients with PiSZ). Two patients (ages 64 and 71 years) were
lifelong nonsmokers, whereas the other patients had a smoking
history of 20  3.3 pack-years. Only 1 patient had received
intravenous 1-antitrypsin substitution (Prolastin). According to a
previously published simple visual chest computed tomographic
(CT) scoring system,16 13 patients had markedly heterogeneous
emphysema, 5 patients had intermediately heterogeneous emphy-
sema, and 3 patients had homogeneous emphysema. The predom-
inant site of destruction was in the lower lobes in 10 cases, in the
upper lobes in 4, and in both lobes in 4. In 15 patients moderate
inflammatory and postinflammatory changes (of these, 2 patients
had bronchiectasis) were visible on the CT scans. We found no
difference with respect to a history of infections or exacerbations
between these patients and those with pure smoker’s emphysema.
Patients were selected for LVRS according to previously pub-
lished criteria.17 Twenty-one patients with pure smoker’s emphy-
sema with comparable sex, age, and baseline pulmonary function
data from our ongoing prospective LVRS study were matched, and
their postoperative results were compared with the A1-ATD pop-
ulation (Table 1). However, it was not possible to match these two
groups with respect to CT morphology, because the patients with
smoker’s emphysema had predominantly heterogeneous emphy-
sema with upper lobe predominance.
Surgical Intervention
Bilateral LVRS was performed by video-assisted endoscopic sta-
ple (buttressed or not buttressed with bovine pericardium).18 The
lung was resected in areas that showed the most severe emphy-
sema on imaging studies (CT scan and quantitative perfusion
scan). In homogeneously destroyed lungs, the site of resection was
preferentially chosen in the upper lobes. In 3 patients LVRS was
performed only unilaterally because of marked destruction and
TABLE 1. Baseline characteristics of patients with A1-ATD
and a matched cohort with smoker’s emphysema
A1-ATD
(n  21)
Smoker’s
emphysema
(n  21)
Female (No.) 10 9
Age (y) 56 2.0 57 1.8
FEV1 (L) 0.78 0.04 0.79 0.05
FEV1 (% predicted) 27 1.9 28 1.9
Residual volume/total lung
capacity ratio
0.67 0.02 0.67 0.02
6-min walk distance (m) 278 20 302 19
Medical Research Council score 3.7 0.1 3.43 0.1
Except for numbers of female patients, all data are mean  SE.hyperinflation on one side. Four patients were operated on only in
The Journal of Thoracithe upper lobes, 10 in the lower lobes, and 7 in both lobes. In 2
patients with complete lower lobe destruction, an anatomic lobec-
tomy was performed. In patients who had a combination of lower
and upper lobe destruction, approximately 20% to 30% of the
upper lobe was resected, in combination with basilar segments of
the lower lobe, and in patients with homogeneous disease, we
resected approximately 40% to 50% of both upper lobes. All
patients were extubated in the operating room.
Measurements
Pulmonary function studies, including spirometry, plethysmogra-
phy, and measurements of carbon monoxide diffusion capacity
according to the European Respiratory Society criteria19,20 were
performed after the inhalation of 2 puffs of albuterol. Dyspnea was
Figure 1. Effect of LVRS on FEV1 through 42 months. Numbers of
patients are given below for each time point. Squares represent
mean; error bars represent SE. Asterisk indicates P < .05 versus
preoperative value.
Figure 2. Effect of LVRS on dyspnea, assessed by Medical Research
Council dyspnea score, through 42 months. Numbers of patients are
given below for each time point. Squares represent mean; error bars
represent SE. Asterisk indicates P < .05 versus preoperative value.rated with the American Thoracic Society modified Medical Re-
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walking distance, the patients walked along the same hospital
hallway without supplemental oxygen. Four patients fulfilled the
criteria for long-term oxygen therapy, although they did not re-
ceive supplemental oxygen during the 6-minute walk. All mea-
surements were taken within 1 month before LVRS, after 3
months, at 6 months, and then at half-annual intervals.
Data Analysis and Statistics
Values are expressed as mean  SE. Paired t tests and analyses of
variance followed by Tukey post hoc test, where appropriate, were
performed to detect differences within the same group or between
groups.
Results
Morbidity and Mortality
The median duration of hospital stay was 10 days (range
7-13 days). The chest tubes were removed after 6  0.5
days. The most common complication was prolonged air
leak (7 days), which occurred in 7 of 21 patients. One
patient needed a reoperation because of a persistent air leak
on postoperative day 7. There was no perioperative mortal-
ity. During the follow-up, 5 patients underwent lung trans-
plantation (3, 24, 36, 40, and 42 months after LVRS). One
patient with unsatisfactory results underwent lung trans-
plantation after 3 months. Three patients died, 2 of respira-
tory failure (at 24 and 42 months). One patient committed
suicide 3 months after surgery despite a good subjective
result at that time.
Functional Results
At the time of analysis, patients had reached various time
points. The follow-up data are summarized in Tables 2 and
TABLE 2. Outcome after LVRS in patients with A1-ATD em
Preoperative 3
No. with f/u* 21
No. without f/u*
No. not yet reached f/u
Cumulative deaths
No. transplanted
FEV1 (L) 0.78 0.0 1.04
FEV1 (% predicted) 27 1.9 38
IVC (L) 2.89 0.1 3.48
IVC (% predicted) 79 4.4 98
RV/TLC 0.67 0.0 0.51
DLCO (% predicted) 37 3 40
pH 7.4 0.0 7.4
PaCO2 (mm Hg) 33.8 0.1 36.6
PaO2 (mm Hg) 63.6 0.3 65.3
6-min walk distance (m) 278 20 365
Dyspnea (MRC score) 3.7 0.1 1.4
Except for numbers of patients, all data are mean  SE. f/u, Follow-up; IV
DLCO, diffusing capacity of carbon monoxide; MRC, Medical Research Co
*The number of patients with and without follow-up refers to patients ali3 for a period extending to 42 months. The mean forced
410 The Journal of Thoracic and Cardiovascular Surgery ● Septexpiratory volume in 1 minute (FEV1) and Medical Re-
search Council dyspnea score are shown in Figures 1 and 2.
The improvements were maximal at 3 to 6 months postop-
eratively and steadily declined thereafter. Before LVRS,
shortness of breath according to the Medical Research
Council dyspnea scale was 3.7  0.1; it improved to 1.4 
0.2 at 3 months. At that point 85% of patients (n  16/18)
had less dyspnea, which remained for as long as 3.5 years in
6 (of 7 who were alive and free of transplantation). Two
patients showed a remarkable increase in FEV1 (mean
FEV1increased at 3 months after LVRS in 50 %), and two
showed a decrease in hyperinflation; both parameters re-
mained improved for as long as 3.5 years after surgery.
Clinical and functional response to LVRS did not statis-
tically correlate with the prospectively assessed emphysema
morphologic types, most probably because of the small
number. Nevertheless, the 4 patients with the longest lasting
functional effects had marked radiologic emphysema heter-
ogeneity; there was marked lung destruction in the lower
lobe in 2 patients and in the upper lobe in the other 2, with
no radiologic signs of airway or parenchymal inflammation.
Results from gas exchange are shown in Table 2. The
mean PaCO2 and the mean PaO2 increased slightly. After 2
years, these findings were no longer present. Four patients
fulfilled criteria for long-term oxygen therapy (PaO2  55
mm Hg) before the operation, whereas at 3 months this was
true only for 1 patient.
We found no difference in the functional outcome (Fig-
ure 3) between the patients with A1-ATD and a cohort with
pure smoker’s emphysema matched for age, sex, and func-
tion. However, because the two patients groups were not
ema
P value 6 mo P value
19
1
1
.1 .005 0.96 0.1 .01
.3 .003 34 3.6 .01
.2 .0003 3.49 0.2 .004
.8 .0005 98 5.9 .006
.3 .0004 0.53 0.1 .003
15.8 40 3 8.3
.0 16.8 7.4 0.0 16.8
.2 .09 36 0.2 .09
.3 .04 67.5 0.3 .01
0 .01 399 20 .02
.2 .0000 1.6 0.2 .0000
spiratory vital capacity; RV/TLC, residual volume/total lung capacity ratio;
.
free of transplantation.phys
mo
19
1
1
 0
 3
 0
 4
 0
 2
 0
 0
 0
 2
 0
C, in
uncil
ve orcomparable with respect to emphysema morphology (no
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this comparison is of limited value.
Discussion
Several groups1,4,5,21,22 have reported long-term results af-
ter LVRS in patients with smoker’s emphysema. However,
in all these reports patients with A1-ATD were either ex-
cluded or only included in very small numbers. The natural
history and morphology of emphysema in smokers with
A1-ATD differ from those of patients with pure smoker’s
emphysema. Nonsmokers with A1-ATD will not show clin-
ically relevant emphysema before the sixth decade. In
smokers with A1-ATD, symptoms of chronic obstructive
pulmonary disease generally start at a much earlier age than
in patients with pure smoker’s emphysema. In addition,
A1-ATD preferentially involves the lower parts of the lung,
rather than the upper lobes, and is often accompanied by
airway inflammation.
Our results demonstrate clinical and physiologic im-
provements in lung function after LVRS in patients with
A1-ATD. We observed an improvement that was maximal
TABLE 3. Proportion of patients with improvement during
Changes 3 mo 6
FEV1 150 mL 10/19 7
Residual volume/total lung capacity
ratio 0.05
17/19 13
Medical Research Council score 1 16/18 17
6-min walk distance 50 m 7/18 7
Data are numbers of patients meeting criteria out of patients evaluated. C
12 mo P value 24 mo P value
15 14
3 2
1 1
1 2
1 2
0.95 0.1 .02 0.84 0.1 .26
34 3.5 .01 30 3.4 .17
3.55 0.2 .003 3.12 0.2 .01
98 5.7 .008 98 6.7 .005
0.54 0.1 .004 0.57 0.1 .005
43 4 9.3 42 3 7.0
7.4 0.0 16.8 7.4 0.0 16.8
36 0.1 .09 36 0.2 .09
67.5 0.2 .01 66 0.4 .02
406 26 .04 367 26 .09
1.7 0.2 .001 2.2 0.3 .003at 3 to 6 months and only slightly inferior to the one
The Journal of Thoraciachieved in pure smoker’s emphysema. Thereafter, a rela-
tively rapid decline of the functional gains occurred in many
cases, but 4 of the studied patients had long-term response
with respect not only to dyspnea but also to lung function.
This is approximately 20% of the entire cohort and is quite
similar to the durability seen in terms of disease-specific
quality of life and exercise capacity in the National Emphy-
sema Treatment Trial.18 Overall the beneficial effects lasted
as long as 2 to 4 years after surgery. These changes were
shorter lasting than those observed in patients with pure
smoker’s emphysema.18 Of 178 patients who underwent
LVRS in our institution and were prospectively assessed for
clinical and functional outcome, we selected 21 persons
matching the 21 patients with A1-ATD emphysema. A
comparison of gain and outcome showed a better result in
the group with pure smoker’s emphysema, but the results
did not differ statistically. This is not surprising, because the
two groups are not comparable with regard to morpholog-
ical severity and distribution of emphysema. Our observa-
tions differ from those of others13 who have reported no
beneficial effect present 12 months after LVRS (Table 3).
w-up period
12 mo 24 mo 36 mo 42 mo
7/15 4/14 3/10 2/7
12/15 7/13 6/10 2/7
11/11 9/11 7/9 6/7
5/11 5/11 2/8 2/7
es are relative to baseline.
36 mo P value 42 mo P value
10 7
3 3
3 3
2 3
3 5
0.75 0.1 .30 0.82 0.2 .36
28 2.5 .21 31 5.6 .31
2.63 0.2 .09 2.81 0.3 .77
80 6.1 .09 83 8.3 .89
0.60 0.1 .43 0.67 0.1 .55
39 4 3.8 46 5 1.7
7.4 0.0 16.8 7.4 0.0 16.8
36.8 0.2 .09 40 0.2 .06
63 0.4 7.0 63 0.4 7.0
343 32 1.50 368 53 1.80
2.57 0.3 .02 1.83 0.5 .01follo
mo
/19
/18
/18
/18They attribute this poor long-term outcome mostly to in-
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by the observation that the 4 patients with long-term re-
sponses in our series had, in contrast to the remainder, no
indicators of inflammatory disease in the CT scan.
Previously, we and others have demonstrated that em-
physema morphologic type is associated with functional
outcome after LVRS; that is, patients with heterogeneous
emphysema have larger functional improvements than do
those with homogeneous disease.16,23 In this series we were
not able to prove such a correlation, most probably because
of the small numbers of study subjects. Nevertheless, our 4
patients with long-term responses not only had no signs of
airway inflammation but had heterogeneous emphysema
with well-preserved pulmonary tissue.
Twelve patients fulfilled the criteria for lung transplan-
tation (age60 years, FEV1 25%, no contraindications to
transplantation, no preoperative hypercapnea, although 2
were hypoxemic) at the time of LVRS. Of those, 6 patients
had an improvement for as long as 3.5 years after LVRS,
and transplantation was not necessary. Six other patients
successfully underwent lung transplantation.
Despite smaller functional gains and a shorter-lasting
effect obtained by LVRS in patients with A1-ATD than in
patients with pure smoker’s emphysema, LVRS served as a
bridging procedure that postponed the need for lung trans-
plantation in most cases. In summary, our data support the
contention that patients with A1-ATD should not be ex-
cluded from LVRS in all cases. Patients with markedly
heterogeneous emphysema and only trivial signs of inflam-
matory changes on CT scan seem to have the greatest
Figure 3. Course of FEV1 through 2 years after LVRS for patients
with A1-ATD (squares) and patients with pure smoker’s emphy-
sema (circles). Numbers of patients are given for each time point,
above for patients with smoker’s emphysema and below for
patients with A1-ATD. Data points represent mean; error bars
represent SE.chance for long-term response. In contrast, patients with
412 The Journal of Thoracic and Cardiovascular Surgery ● Septadvanced homogeneous lung destruction and inflammatory
airway disease should be preferentially directed to lung
transplantation if possible.
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Discussion
Dr Malcolm M. DeCamp, Jr (Cleveland, Ohio). One of the most
vexing controversies in LVRS is that of patient selection. Tutic and
colleagues from Zurich are to be congratulated for tackling this
issue in a unique subset of patients, those with emphysema not
from smoking alone but from 1-antitrypsin deficiency.
The strengths of their work are their well-characterized patients
with detailed assessments of anatomy, physiology, and function.
The weaknesses of this report are the small size of the cohort, the
fact that there was no control arm, and the surprisingly variable
morphology of these patients despite sharing a deficient genotype.
Only 9 of the 21 patients, just less than 50%, had the classic
lower lobe distribution of A1-ATD. That has to be taken into
account when we look at these results. More importantly, I think
the group elegantly showed that after LVRS there was a discon-
nection between the measured physiologic benefit, the functional
benefit, and the perception of dyspnea. These outcomes deterio-
rated at varying rates after LVRS.
I have the following questions for Dr Tutic. First, given the
variable pattern of emphysema, how do you standardize the video-
assisted thoracoscopic resection? Some of these patients had pre-
dominantly upper lobe disease, some had lower lobe disease, some
had both, and some had diffuse emphysema.
Dr Tutic. Thank you for your questions. Dr Weder will answer
them. He is the surgeon who is performing the LVRS.
Dr Weder. Thank you, Dr. DeCamp, for all these questions.
First, regarding the morphology and the expected lower lobe
predominance of emphysema in patients with A1-ATD, indeed not
all the patients operated on showed the typical distribution. This
was clearly the case for only half the patients. Additionally, 2 other
patients had lower lobe destruction but also some destruction in the
upper lobe. Five with what we call intermediate type of heteroge-
neity had a difference in destruction, but in an area smaller than the
size of a segment. Most of them had it in their lower lobe as well,
so we are probably talking about approximately 2 thirds of patients
with predominance of destruction in the lower lobes.
The Journal of ThoraciNow, how did we standardize our surgical procedure? For
typical lower lobe disease we either performed a lower lobe
resection, which we did in 2 cases, or if we resected the basilar
segments, we freed the pulmonary ligament and then started the
resection distal to the inferior pulmonary vein, heading more or
less horizontally. In patients with a combination of lower lobe and
upper lobe disease, of course we resected a piece of the upper lobe
as well, and in patients with homogeneous disease, we usually
resected in the upper lobe because we believe the shape of the lung
is better when the resection is done in the upper lobe.
Dr DeCamp. Along those same lines, how did your operative
morbidity, specifically air leak, in this cohort of patients with
A1-ATD compare with your previous experience in standard to-
bacco-induced emphysema LVRS?
Dr Weder. It was slightly better than with smoker’s emphy-
sema. We had a 10-day hospital stay and a mean duration of
drainage of 6 days, and only a third had more than 7 days of air
leaks. One patient was reoperated on because of prolonged air
leak.
Dr DeCamp. To get at one of the take-home messages, where
you say 30% of your patients have long-term functional benefit, I
wonder if you could clarify that. Tell me, of the original 21
patients that you entered into this study, what percentage of them
really had functional benefit at 3 years?
Dr Weder. If we include all patients from the beginning, 80%
had functional benefit measured by FEV1, and measured by the
Medical Research Council at 6 months, 36% still had a benefit at
3.5 years.
Dr DeCamp. But in your article you talk about 2 of 7 patients.
Dr Weder. Yes, this is correct.
Dr DeCamp. That excludes the deaths and the patients that are
transplanted. So with respect to the validity of the statistics, I think
it can be somewhat misleading. It’s 30% of the surviving, non-
transplanted patients that are still benefiting, not 30% of the
original cohort.
Dr Weder. Yes, this is correct.
Dr DeCamp. Finally, one of the points that you make very
nicely in the article is that for those patients that do benefit, you
can forestall the need for lung transplantation as long as 3 years.
How would you select a patient who should use LVRS as a bridge,
if you will, to transplantation versus a patient for whom LVRS is
more futile and should go directly towards transplantation?
Dr Weder. Because we have observed some patients to have
really a great benefit at 3.5 years and beyond, we went back to look
at all the CT scans again. The individuals who had a long-term
benefit showed two characteristics. The first was a clear heteroge-
neity of the destruction of the lung, with well-preserved lung
beside a largely destroyed lung. The second was practically no sign
of chronic inflammatory airway disease; they had no bronchiecta-
sis and also no scarring. So I think the patient that you really
should consider for LVRS instead of lung transplantation is this
type of patient, whereas the other patients who have a relatively
advanced destruction of the lung and additionally signs of chronic
airway disease should in my opinion be directed to lung transplan-
tation beforehand.
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